The estimated Net Worth of Patricia A. Turney is at least $1.49 Milion dollars as of 6 March 2023. Ms. Turney owns over 831 units of Arcutis Biotherapeutics Inc stock worth over $661,308 and over the last 5 years she sold ARQT stock worth over $116,568. In addition, she makes $713,713 as Senior Vice President - Manufacturing at Arcutis Biotherapeutics Inc.
Sign up
Ms. Turney ARQT stock SEC Form 4 insiders trading
Patricia has made over 5 trades of the Arcutis Biotherapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently she sold 831 units of ARQT stock worth $12,681 on 6 March 2023.
The largest trade she's ever made was selling 2,368 units of Arcutis Biotherapeutics Inc stock on 28 February 2023 worth over $37,793. On average, Patricia trades about 677 units every 82 days since 2020. As of 6 March 2023 she still owns at least 62,862 units of Arcutis Biotherapeutics Inc stock.
You can see the complete history of Ms. Turney stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Patricia Turney biography
Patricia A. Turney serves as Senior Vice President - Manufacturing of the Company. Prior to joining Arcutis, she was Vice President, External Supply for Amgen, Inc., where she was responsible for the manufacture of over $5B in annual product sales, more than 250 external suppliers, and 55 contract manufacturing sites spanning 10 countries. Previously, she led Amgen’s Manufacturing Site Operations in The Netherlands, supplying patients in over 75 countries. Ms. Turney served with Amgen for more than 23 years, and held a wide variety of leadership roles with increasing responsibility within Manufacturing, Engineering, EH&S, R&D, and Quality. She received her B.S. in Mathematics and Engineering from the US Naval Academy, and her M.B.A. from UCLA’s Anderson School of Management. Prior to her career at Amgen, Ms. Turney was a U.S. Naval Aviator and served in the US Navy in various locations around the world.
What is the salary of Patricia Turney?
As the Senior Vice President - Manufacturing of Arcutis Biotherapeutics Inc, the total compensation of Patricia Turney at Arcutis Biotherapeutics Inc is $713,713. There are 3 executives at Arcutis Biotherapeutics Inc getting paid more, with Todd Watanabe having the highest compensation of $1,140,300.
How old is Patricia Turney?
Patricia Turney is 53, she's been the Senior Vice President - Manufacturing of Arcutis Biotherapeutics Inc since 2019. There are 11 older and 15 younger executives at Arcutis Biotherapeutics Inc. The oldest executive at Arcutis Biotherapeutics Inc is Howard Welgus, 68, who is the Director.
What's Patricia Turney's mailing address?
Patricia's mailing address filed with the SEC is C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE, CA, 91361.
Insiders trading at Arcutis Biotherapeutics Inc
Over the last 5 years, insiders at Arcutis Biotherapeutics Inc have traded over $33,184,604 worth of Arcutis Biotherapeutics Inc stock and bought 3,754,945 units worth $71,202,175 . The most active insiders traders include Jonathan Silverstein, Patrick J Heron a Advisors Llcorbimed Capital.... On average, Arcutis Biotherapeutics Inc executives and independent directors trade stock every 10 days with the average trade being worth of $361,425. The most recent stock trade was executed by Howard G. Welgus on 3 September 2024, trading 10,000 units of ARQT stock currently worth $107,700.
What does Arcutis Biotherapeutics Inc do?
arcutis biotherapeutics, inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. its lead product candidate is arq-151, a topical cream formulation of roflumilast that is in phase iii clinical trials for the treatment of plaque psoriasis and atopic dermatitis. the company is also developing arq-154, a topical foam formulation of arq-151 for the treatment of seborrheic dermatitis and scalp psoriasis; arq-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and arq-255, a topical formulation of arq-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. the company was formerly known as arcutis, inc. and changed its name to arcutis biotherapeutics, inc. in october 2019. arcutis biotherapeutics, inc. was founded in 2016 and is headquartered in westlake village, california.
What does Arcutis Biotherapeutics Inc's logo look like?
Complete history of Ms. Turney stock trades at Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics Inc executives and stock owners
Arcutis Biotherapeutics Inc executives and other stock owners filed with the SEC include:
-
Todd Watanabe,
President, Chief Executive Officer, Director -
Kenneth Lock,
Chief Commercial Officer -
Todd Franklin Watanabe M.A.,
Pres, CEO & Director -
Patricia Turney,
Senior Vice President - Manufacturing -
Dr. Patrick E. Burnett M.D., Ph.D.,
Sr. VP & Chief Medical Officer -
Kenneth A. Lock,
Chief Commercial Officer -
Bhaskar Chaudhuri,
Independent Director -
Joseph Turner,
Independent Director -
Ricky Sun,
Independent Director -
Jonathan Silverstein,
Independent Director -
Howard Welgus,
Director -
Halley Gilbert,
Director -
Terrie Curran,
Director -
Patrick Burnett,
Chief Medical Officer -
Keith Klein,
General Counsel -
Frank Pompilio,
Vice President - Medical Affairs -
Lynn Navale,
Vice President - Biometrics -
Charlotte Merritt,
Vice President - Regulatory Affairs -
Ayisha Jeter,
Vice President of Market Access -
Meg Elias,
Vice President - Clinical Operations -
Bethany Dudek,
Vice President - Quality -
David Berk,
Vice President - Clinical Development -
Heather Armstrong,
Vice President of Investor Relations and Corporate Communications -
Kimberly Lathroum,
Vice President of Marketing -
Jay Ramsinghani,
Vice President of Commercial Strategy and Operations -
Scott Burrows,
Vice President - Finance -
John Smither,
Chief Financial Officer -
David Osborne,
Co-Founder, Chief Technical Officer -
Patrick Heron,
Independent Chairman of the Board -
Masaru Matsuda Esq., J.D.,
Gen. Counsel & Corp. Sec. -
Courtney Barton,
Chief Compliance Officer, VP, Chief of Staff & Chief Privacy Officer -
Eric McIntyre,
Head of Investor Relations -
Dr. David W. Osborne,
Chief Technical Officer -
Patricia A. Turney,
Sr. VP of Operations -
Scott L. Burrows,
CFO & Principal Accounting Officer -
Larry Todd Edwards,
SVP Chief Commercial Officer -
Daniel Estes,
Director -
Neha Krishnamohan,
Director -
David Joseph Topper,
Chief Financial Officer -
Masaru Matsuda,
See Remarks -
Capital Life Sciences Inves...,
-
Advisors Llcorbimed Capital...,
-
Life Sciences Viii, L.P.Fhm...,
-
Matthew Richard Moore,
SVP and Chief Business Officer -
Life Sciences Viii, L.P.Fhm...,
-
Sue Jean Lin,
Director -
Keith R Leonard,
Director -
Life Sciences Viii, L.P.Fhm...,